MCID: BRS099
MIFTS: 57

Breast Ductal Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Breast Ductal Carcinoma

MalaCards integrated aliases for Breast Ductal Carcinoma:

Name: Breast Ductal Carcinoma 12 15
Ductal Breast Carcinoma 56 6 74
Mammary Ductal Carcinoma 74
Carcinoma, Ductal 45
Ductal Carcinoma 74
Duct Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3007
MeSH 45 D044584
SNOMED-CT 69 82711006

Summaries for Breast Ductal Carcinoma

Disease Ontology : 12 A breast carcinoma that derives from the lining of milk ducts.

MalaCards based summary : Breast Ductal Carcinoma, also known as ductal breast carcinoma, is related to bile duct cancer and comedo carcinoma. An important gene associated with Breast Ductal Carcinoma is RAD54L (RAD54 Like), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Pertuzumab and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and skin, and related phenotypes are Decreased cell migration and Decreased viability in esophageal squamous lineage

Related Diseases for Breast Ductal Carcinoma

Diseases related to Breast Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 299)
# Related Disease Score Top Affiliating Genes
1 bile duct cancer 32.8 CCND1 EGFR MET TP53
2 comedo carcinoma 32.8 ERBB2 ESR1
3 renal cell carcinoma, nonpapillary 32.5 CDH1 EGFR KRT8 MET
4 intrahepatic cholangiocarcinoma 32.4 CDH1 CTNNB1 EGFR TP53
5 breast cystic hypersecretory carcinoma 32.4 CDH1 ERBB2
6 cholangiocarcinoma 31.3 CCND1 CDH1 CTNNB1 EGFR ERBB2 KRT8
7 pleomorphic adenoma carcinoma 31.2 ERBB2 TP53
8 in situ carcinoma 31.0 BRCA1 CDH1 EGFR ERBB2 ESR1 PGR
9 pleomorphic adenoma 30.7 AR ERBB2 TP53
10 renal cell carcinoma, papillary, 1 30.4 ERBB2 MET TP53
11 adenocarcinoma 30.3 CCND1 CDH1 CTNNB1 EGFR ERBB2 TP53
12 cystadenocarcinoma 30.1 ERBB2 PGR TP53
13 transitional cell carcinoma 29.9 CDH1 EGFR ERBB2 KRT8 TP53
14 ductal carcinoma in situ 29.9 AR BRCA1 CCND1 CDH1 EGFR ERBB2
15 adenoid cystic carcinoma 29.8 CCND1 CDH1 CTNNB1 ERBB2 PGR TP53
16 breast carcinoma in situ 29.8 BRCA1 EGFR ERBB2 ESR1 MET PGR
17 papillary carcinoma 29.8 CDH1 ERBB2 MET PGR
18 bladder urothelial carcinoma 29.6 CCND1 CDH1 CTNNB1 ERBB2 TP53 VEGFC
19 thyroid cancer 29.6 CCND1 CDH1 CTNNB1 EGFR MET TP53
20 sweat gland cancer 29.5 ERBB2 ESR1 KRT8 PGR TP53
21 squamous cell carcinoma 29.5 CCND1 CDH1 CTNNB1 EGFR ERBB2 NME1
22 breast disease 29.4 BRCA1 CTSD ERBB2 ESR1 PGR TFF1
23 mammary paget's disease 29.4 EGFR ERBB2 ESR1 KRT8 PGR
24 breast fibroadenoma 29.2 ERBB2 ESR1 KRT8 NME1 PGR
25 breast cancer 26.0 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
26 collecting duct carcinoma 12.6
27 adenosquamous bile duct carcinoma 12.3
28 bile duct carcinoma in situ 12.2
29 nipple duct carcinoma 12.1
30 squamous cell bile duct carcinoma 12.0
31 distal biliary tract carcinoma 11.4
32 cribriform carcinoma 11.1
33 klatskin's tumor 11.0
34 extrahepatic bile duct small cell adenocarcinoma 11.0
35 renal cell carcinoma, xp11-associated 11.0
36 extrahepatic bile duct adenocarcinoma 11.0
37 bile duct adenocarcinoma 11.0
38 cerebral convexity meningioma 10.6 CDH1 TP53
39 gastric papillary adenocarcinoma 10.6 ERBB2 TP53
40 adult hepatocellular carcinoma 10.5 CTNNB1 TP53
41 breast papillomatosis 10.5 CCND1 ERBB2
42 breast malignant phyllodes tumor 10.5 PGR TP53
43 childhood hepatocellular carcinoma 10.5 CTNNB1 MET
44 brain ependymoma 10.5 EGFR TP53
45 recurrent respiratory papillomatosis 10.5 EGFR TP53
46 intracystic papillary adenoma 10.5 ERBB2 PGR
47 breast metaplastic carcinoma 10.5 ERBB2 PGR
48 vulvar benign neoplasm 10.5 ESR1 PGR
49 trigonitis 10.5 ESR1 PGR
50 bartholin's gland benign neoplasm 10.5 ESR1 PGR

Graphical network of the top 20 diseases related to Breast Ductal Carcinoma:



Diseases related to Breast Ductal Carcinoma

Symptoms & Phenotypes for Breast Ductal Carcinoma

GenomeRNAi Phenotypes related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.65 CTNNB1 CTSD EGFR MET VEGFC
2 Decreased viability in esophageal squamous lineage GR00235-A 9.65 BRCA1 CCND1 CDH1 CTNNB1 ERBB2 ESR1
3 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 CTNNB1 CTSD EGFR ERBB2 VEGFC
4 Increased cell death HMECs cells GR00103-A-0 9.1 BRCA1 CTNNB1 EGFR PGR PIP TP53

MGI Mouse Phenotypes related to Breast Ductal Carcinoma:

47 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.46 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
2 cellular MP:0005384 10.46 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
3 homeostasis/metabolism MP:0005376 10.46 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
4 digestive/alimentary MP:0005381 10.44 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
5 endocrine/exocrine gland MP:0005379 10.43 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
6 growth/size/body region MP:0005378 10.42 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
7 immune system MP:0005387 10.42 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
8 mortality/aging MP:0010768 10.4 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
9 hematopoietic system MP:0005397 10.35 AR BRCA1 CCND1 CTNNB1 CTSD EGFR
10 embryo MP:0005380 10.33 AR BRCA1 CDH1 CTNNB1 EGFR ERBB2
11 integument MP:0010771 10.31 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
12 neoplasm MP:0002006 10.27 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
13 limbs/digits/tail MP:0005371 10.18 AR BRCA1 CTNNB1 EGFR ERBB2 ESR1
14 nervous system MP:0003631 10.17 AR BRCA1 CCND1 CTNNB1 CTSD EGFR
15 craniofacial MP:0005382 10.15 AR CCND1 CTNNB1 EGFR ERBB2 MET
16 normal MP:0002873 10.15 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
17 muscle MP:0005369 10.13 AR BRCA1 CTNNB1 EGFR ERBB2 ESR1
18 liver/biliary system MP:0005370 10.11 AR CTNNB1 EGFR ESR1 KRT8 MET
19 no phenotypic analysis MP:0003012 9.95 CDH1 CTNNB1 EGFR ESR1 MET PGR
20 reproductive system MP:0005389 9.93 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
21 renal/urinary system MP:0005367 9.8 AR BRCA1 CTNNB1 EGFR ESR1 MET
22 pigmentation MP:0001186 9.72 AR BRCA1 CTNNB1 EGFR TP53
23 respiratory system MP:0005388 9.56 BRCA1 CCND1 CTNNB1 EGFR ERBB2 ESR1
24 skeleton MP:0005390 9.28 AR BRCA1 CCND1 CTNNB1 EGFR ERBB2

Drugs & Therapeutics for Breast Ductal Carcinoma

Drugs for Breast Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 192)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pertuzumab Approved Phase 3,Phase 2 380610-27-5, 145040-37-5 2540
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
4
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
5
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
6
Tamoxifen Approved Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
7
Sodium Citrate Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
8
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
9
Fulvestrant Approved, Investigational Phase 3,Phase 2,Not Applicable 129453-61-8 104741 17756771
10
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 57-83-0 5994
11
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
12
Trastuzumab Approved, Investigational Phase 2, Phase 3,Phase 3 180288-69-1 9903
13
Carboplatin Approved Phase 2, Phase 3,Phase 3 41575-94-4 38904 10339178 498142
14
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
15
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
16
Letrozole Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 112809-51-5 3902
17
Toremifene Approved, Investigational Phase 3 89778-26-7 3005573
18
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
19
Cisplatin Approved Phase 3,Phase 2 15663-27-1 441203 84093 2767
20
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
21
Fluorouracil Approved Phase 3,Phase 1 51-21-8 3385
22
Metformin Approved Phase 3 657-24-9 14219 4091
23
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
24
Goserelin Approved Phase 2, Phase 3 65807-02-5 5311128 47725
25
Leuprolide Approved, Investigational Phase 2, Phase 3 53714-56-0 657181 3911
26
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
27
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
28
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
29
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 77-92-9 311
30
Calcium Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
31
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
32
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Not Applicable 388082-78-8, 231277-92-2 208908 9941095
33 Atamestane Investigational Phase 3 96301-34-7
34 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
35 Antimitotic Agents Phase 3,Phase 2,Phase 1
36 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
37 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
38 Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1,Not Applicable
39 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1,Not Applicable
40 Estrogen Receptor Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
41 Citrate Phase 3,Phase 2,Phase 1,Not Applicable
42 Steroid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
44 Estrogen Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
45 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
46 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
47 Estrogens Phase 3,Phase 2,Phase 1,Not Applicable
48 Aromatase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
49 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 167)
# Name Status NCT ID Phase Drugs
1 Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Unknown status NCT01583426 Phase 3 nab-Paclitaxel;Paclitaxel
2 Circulating Tumor Cells to Guide Chemotherapy for Metastatic Breast Cancer Completed NCT01349842 Phase 3
3 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
4 Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer Completed NCT00002967 Phase 3 cyclophosphamide;doxorubicin hydrochloride;octreotide pamoate;tamoxifen citrate
5 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
6 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Completed NCT02125344 Phase 3 non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
7 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
8 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
9 Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer Completed NCT00004205 Phase 3 letrozole;tamoxifen citrate
10 Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer Completed NCT00044291 Phase 3 atamestane;toremifene;letrozole;aromatase inhibition
11 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
12 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
13 Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women Recruiting NCT03201861 Phase 3 Paclitaxel, Cisplatin;EC to docetaxel or paclitaxel
14 Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy Recruiting NCT02879513 Phase 3 Paclitaxel;Cisplatin;Epirubicin;Cyclophosphamide;5-fluoruracil
15 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer Recruiting NCT01905046 Phase 3 metformin hydrochloride
16 Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer Recruiting NCT03414970 Phase 3
17 Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Recruiting NCT01953588 Phase 3 fulvestrant;anastrozole
18 Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 Active, not recruiting NCT02620280 Phase 3 Carboplatin;Abraxane;MPDL3280A;Anthra
19 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
20 Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS) Active, not recruiting NCT00907868 Phase 3
21 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
22 Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
23 Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients Active, not recruiting NCT02221999 Phase 2, Phase 3 Paclitaxel;Cisplatin;Gonadotropin-releasing hormone agonist;Letrozole
24 Oxybutynin Chloride in Managing Hot Flashes Active, not recruiting NCT02961790 Phase 3 Oxybutynin Chloride
25 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
26 Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes Active, not recruiting NCT00433589 Phase 3 anthracycline-based;docetaxel and capecitabine
27 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
28 Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer Terminated NCT00267553 Phase 3 Atamestane;toremifene;letrozole
29 The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer Terminated NCT00097344 Phase 3 Atamestane;Toremifene;Letrozole;Aromatase inhibition;Estrogen receptor blocker
30 Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS Withdrawn NCT00324714 Phase 3 risedronate sodium
31 Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
32 Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
33 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
34 Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ Completed NCT01439711 Phase 2 letrozole
35 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Completed NCT02150525 Phase 2
36 Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer Completed NCT02199418 Phase 2 Paclitaxel;Cisplatin
37 Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer Completed NCT00416403 Phase 2 fluvastatin sodium
38 Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy Completed NCT00843167 Phase 2
39 Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer Completed NCT00960336 Phase 2 pegylated liposomal doxorubicin hydrochloride
40 Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer Completed NCT00182793 Phase 2 carboplatin;cyclophosphamide;melphalan;thiotepa
41 Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer Completed NCT00054301 Phase 2
42 Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer Completed NCT00002873 Phase 1, Phase 2
43 Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer Completed NCT01869764 Phase 2
44 Breast-Conserving Surgery Techniques in Treating Women With Breast Cancer Completed NCT00870415 Phase 2
45 Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer Completed NCT00616967 Phase 2 carboplatin;paclitaxel albumin-stabilized nanoparticle formulation;vorinostat
46 Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer Completed NCT00096343 Phase 2 carboplatin;paclitaxel
47 Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer Completed NCT00334542 Phase 2 simvastatin
48 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
49 Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer Completed NCT00354640 Phase 2 anastrozole;simvastatin
50 Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen Completed NCT00764322 Phase 2 tamoxifen citrate

Search NIH Clinical Center for Breast Ductal Carcinoma

Cochrane evidence based reviews: carcinoma, ductal

Genetic Tests for Breast Ductal Carcinoma

Anatomical Context for Breast Ductal Carcinoma

MalaCards organs/tissues related to Breast Ductal Carcinoma:

42
Breast, Lymph Node, Skin, Bone, Testes, Liver, T Cells

Publications for Breast Ductal Carcinoma

Articles related to Breast Ductal Carcinoma:

(show top 50) (show all 337)
# Title Authors Year
1
Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion: Retrospective observational study. ( 30608397 )
2019
2
Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. ( 30653209 )
2019
3
MNK1/NODAL signaling promotes invasive progression of breast ductal carcinoma in situ. ( 30659022 )
2019
4
Identification of aberrant gene expression during breast ductal carcinoma in situ progression to invasive ductal carcinoma. ( 30712460 )
2019
5
The prognostic significance of lysosomal protective protein (Cathepsin A) in breast ductal carcinoma in situ. ( 30725481 )
2019
6
Frequency of Epstein–Barr Virus DNA in Formalin-Fixed Paraffin-Embedded Tissue of Patients with Ductal Breast Carcinoma ( 30909665 )
2019
7
Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. ( 29955142 )
2018
8
Development of ipsilateral chest wall spindle cell carcinoma in a patient with invasive ductal breast carcinoma during postoperative adjuvant therapy: A case report. ( 29742739 )
2018
9
Breast lymphoma occurring after an invasive ductal breast carcinoma developed in the same area: A case report and literature review. ( 29657120 )
2018
10
Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. ( 29394917 )
2018
11
Overtreatment in surgery - does it concern also the patients with ductal breast carcinoma in situ. ( 29513252 )
2018
12
Aberrant Expression of PIWIL1 and PIWIL2 and Their Clinical Significance in Ductal Breast Carcinoma. ( 29599319 )
2018
13
Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery. ( 29709458 )
2018
14
Evaluation of survivin immunoexpression in the differentiation of high- and low-grade breast ductal carcinoma in situ. ( 29694611 )
2018
15
A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk. ( 30054280 )
2018
16
Computational Feasibility Analysis of Electrochemotherapy With Novel Needle-Electrode Arrays for the Treatment of Invasive Breast Ductal Carcinoma. ( 30157721 )
2018
17
A clinical application of dynamic contrast-enhanced CT (DCE-CT) in patients with variously differentiated breast ductal carcinoma. ( 30198882 )
2018
18
Immunohistochemical Expression of Nanog and Its Relation with Clinicopathologic Characteristics in Breast Ductal Carcinoma ( 30220190 )
2018
19
Functional Role of microRNAs in the Progression of Breast Ductal Carcinoma in situ. ( 30273605 )
2018
20
Morphologic and Molecular Features of Breast Ductal Carcinoma In Situ. ( 30385094 )
2018
21
Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). ( 30410060 )
2018
22
Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. ( 30429518 )
2018
23
Possible predictive role of cancer/testis antigens in breast ductal carcinoma in situ. ( 30546463 )
2018
24
Molecular Evaluation of Breast Ductal Carcinoma in Situ with Oncotype DX DCIS. ( 30605628 )
2018
25
Breast ductal carcinoma with coexistent microfilaria: Diagnosed on cytology. ( 30693217 )
2018
26
Corrigendum: Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma. ( 30068734 )
2018
27
Comparison of Syndecan-1 Immunohistochemical Expression in Lobular and Ductal Breast Carcinoma with Nodal Metastases. ( 30151336 )
2018
28
Contradictory mRNA and protein misexpression of EEF1A1 in ductal breast carcinoma due to cell cycle regulation and cellular stress. ( 30224719 )
2018
29
Colonic metastasis from infiltrating ductal breast carcinoma in a male patient: A case report. ( 30513496 )
2018
30
Integrated landscape of copy number variation and RNA expression associated with nodal metastasis in invasive ductal breast carcinoma. ( 30627325 )
2018
31
Endometrial Metastasis from Ductal Breast Carcinoma: A Case Report with Literature Review. ( 29700276 )
2018
32
Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. ( 29739984 )
2018
33
The Role of CHI3L1 Expression in Angiogenesis in Invasive Ductal Breast Carcinoma. ( 29848684 )
2018
34
Association of conventional ultrasound, elastography and clinicopathological factors with axillary lymph node status in invasive ductal breast carcinoma with sizes > 10 mm. ( 29416814 )
2018
35
Tenascin C is a prognostic determinant and potential cancer-associated fibroblasts marker for breast ductal carcinoma. ( 28223108 )
2017
36
Effect of radiotherapy after breast-conserving surgery in older patients with early breast cancer and breast ductal carcinoma in situ: a meta-analysis. ( 28415667 )
2017
37
(18)F-fluorodeoxyglucose uptake as predictor for invasion in preoperatively diagnosed breast ductal carcinoma in situ: Significance in cases without mass formation. ( 28781782 )
2017
38
Gli1 is a potential cancer stem cell marker and predicts poor prognosis in ductal breast carcinoma. ( 28965964 )
2017
39
IQ-domain GTPase-activating protein 1 promotes the malignant phenotype of invasive ductal breast carcinoma via canonical Wnt pathway. ( 28618949 )
2017
40
The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study. ( 29096155 )
2017
41
Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ. ( 28885232 )
2017
42
Down-regulation of C35 decreased the cell viability and migration of breast ductal carcinoma cells. ( 28859163 )
2017
43
Spatial distribution of mast cells and macrophages around tumor glands in human breast ductal carcinoma. ( 28756894 )
2017
44
Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort. ( 28286675 )
2017
45
Quantitatively characterizing the microstructural features of breast ductal carcinoma tissues in different progression stages by Mueller matrix microscope. ( 28856041 )
2017
46
Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. ( 28338653 )
2017
47
Management of breast ductal carcinoma in situ in Catalonia, Spain: Results from the Grup Oncologic CalalA -OccitA -Catalonia survey with 9-year follow up. ( 28806663 )
2017
48
Correlation Between Expression of Twist and Podoplanin in Ductal Breast Carcinoma. ( 28982860 )
2017
49
Overexpression of TNFAIP8 is associated with tumor aggressiveness and poor prognosis in patients with invasive ductal breast carcinoma. ( 28087477 )
2017
50
Breast ductal carcinoma in situ in an unscreened population: presentation, diagnosis and management at a single tertiary centre. ( 28876551 )
2017

Variations for Breast Ductal Carcinoma

ClinVar genetic disease variations for Breast Ductal Carcinoma:

6 (show top 50) (show all 322)
# Gene Variation Type Significance SNP ID Assembly Location
1 SYT6 NM_001270805.1(SYT6): c.1216G> A (p.Ala406Thr) single nucleotide variant Uncertain significance rs142164979 GRCh37 Chromosome 1, 114640393: 114640393
2 SYT6 NM_001270805.1(SYT6): c.1216G> A (p.Ala406Thr) single nucleotide variant Uncertain significance rs142164979 GRCh38 Chromosome 1, 114097771: 114097771
3 ZDBF2 NM_020923.2(ZDBF2): c.5795G> A (p.Arg1932His) single nucleotide variant Uncertain significance rs763186071 GRCh37 Chromosome 2, 207175047: 207175047
4 ZDBF2 NM_020923.2(ZDBF2): c.5795G> A (p.Arg1932His) single nucleotide variant Uncertain significance rs763186071 GRCh38 Chromosome 2, 206310323: 206310323
5 YEATS2 NM_018023.4(YEATS2): c.3131C> T (p.Pro1044Leu) single nucleotide variant Uncertain significance rs376025260 GRCh37 Chromosome 3, 183515744: 183515744
6 YEATS2 NM_018023.4(YEATS2): c.3131C> T (p.Pro1044Leu) single nucleotide variant Uncertain significance rs376025260 GRCh38 Chromosome 3, 183797956: 183797956
7 PHF24 NM_001304333.2(PHF24): c.242G> A (p.Arg81Gln) single nucleotide variant Uncertain significance rs374394658 GRCh37 Chromosome 9, 34971537: 34971537
8 PHF24 NM_001304333.2(PHF24): c.242G> A (p.Arg81Gln) single nucleotide variant Uncertain significance rs374394658 GRCh38 Chromosome 9, 34971540: 34971540
9 CCDC180 NM_020893.3(CCDC180): c.1975C> G (p.Pro659Ala) single nucleotide variant Uncertain significance rs869025225 GRCh37 Chromosome 9, 100092618: 100092618
10 CCDC180 NM_020893.3(CCDC180): c.1975C> G (p.Pro659Ala) single nucleotide variant Uncertain significance rs869025225 GRCh38 Chromosome 9, 97330336: 97330336
11 CNNM1 NM_020348.2(CNNM1): c.957G> C (p.Glu319Asp) single nucleotide variant Uncertain significance rs869025226 GRCh37 Chromosome 10, 101090101: 101090101
12 CNNM1 NM_020348.2(CNNM1): c.957G> C (p.Glu319Asp) single nucleotide variant Uncertain significance rs869025226 GRCh38 Chromosome 10, 99330344: 99330344
13 MICAL2 NM_014632.3(MICAL2): c.3131A> G (p.Asp1044Gly) single nucleotide variant Uncertain significance rs869025227 GRCh37 Chromosome 11, 12278507: 12278507
14 MICAL2 NM_014632.3(MICAL2): c.3131A> G (p.Asp1044Gly) single nucleotide variant Uncertain significance rs869025227 GRCh38 Chromosome 11, 12256960: 12256960
15 KDM4E NM_001161630.1(KDM4E): c.1493A> G (p.Asn498Ser) single nucleotide variant Uncertain significance rs869025228 GRCh37 Chromosome 11, 94760214: 94760214
16 KDM4E NM_001161630.1(KDM4E): c.1493A> G (p.Asn498Ser) single nucleotide variant Uncertain significance rs869025228 GRCh38 Chromosome 11, 95027050: 95027050
17 TSPAN8 NM_004616.2(TSPAN8): c.528T> A (p.Asp176Glu) single nucleotide variant Uncertain significance rs869025229 GRCh37 Chromosome 12, 71526521: 71526521
18 TSPAN8 NM_004616.2(TSPAN8): c.528T> A (p.Asp176Glu) single nucleotide variant Uncertain significance rs869025229 GRCh38 Chromosome 12, 71132741: 71132741
19 CORO6 NM_032854.3(CORO6): c.1348G> A (p.Val450Met) single nucleotide variant Uncertain significance rs772136445 GRCh37 Chromosome 17, 27942821: 27942821
20 CORO6 NM_032854.3(CORO6): c.1348G> A (p.Val450Met) single nucleotide variant Uncertain significance rs772136445 GRCh38 Chromosome 17, 29615803: 29615803
21 NOTCH3 NM_000435.2(NOTCH3): c.5161T> A (p.Trp1721Arg) single nucleotide variant Uncertain significance rs869025230 GRCh37 Chromosome 19, 15280935: 15280935
22 NOTCH3 NM_000435.2(NOTCH3): c.5161T> A (p.Trp1721Arg) single nucleotide variant Uncertain significance rs869025230 GRCh38 Chromosome 19, 15170124: 15170124
23 CPAMD8 NM_015692.4(CPAMD8): c.4015G> A (p.Ala1339Thr) single nucleotide variant Uncertain significance rs869025231 GRCh37 Chromosome 19, 17017774: 17017774
24 CPAMD8 NM_015692.4(CPAMD8): c.4015G> A (p.Ala1339Thr) single nucleotide variant Uncertain significance rs869025231 GRCh38 Chromosome 19, 16906964: 16906964
25 ZNF420 NM_001329517.1(ZNF420): c.149A> G (p.Asn50Ser) single nucleotide variant Uncertain significance rs771433810 GRCh37 Chromosome 19, 37618255: 37618255
26 ZNF420 NM_001329517.1(ZNF420): c.149A> G (p.Asn50Ser) single nucleotide variant Uncertain significance rs771433810 GRCh38 Chromosome 19, 37127353: 37127353
27 ZNF473 NM_015428.3(ZNF473): c.2359A> T (p.Arg787Ter) single nucleotide variant Uncertain significance rs869025232 GRCh37 Chromosome 19, 50550059: 50550059
28 ZNF473 NM_015428.3(ZNF473): c.2359A> T (p.Arg787Ter) single nucleotide variant Uncertain significance rs869025232 GRCh38 Chromosome 19, 50046802: 50046802
29 KRTAP10-3 NM_198696.2(KRTAP10-3): c.7A> G (p.Thr3Ala) single nucleotide variant Uncertain significance rs452472 GRCh37 Chromosome 21, 45978592: 45978592
30 KRTAP10-3 NM_198696.2(KRTAP10-3): c.7A> G (p.Thr3Ala) single nucleotide variant Uncertain significance rs452472 GRCh38 Chromosome 21, 44558709: 44558709
31 CCDC71L NM_175884.5(CCDC71L): c.478A> C (p.Ser160Arg) single nucleotide variant Uncertain significance rs869025233 GRCh37 Chromosome 7, 106300865: 106300865
32 CCDC71L NM_175884.5(CCDC71L): c.478A> C (p.Ser160Arg) single nucleotide variant Uncertain significance rs869025233 GRCh38 Chromosome 7, 106660419: 106660419
33 HTRA2 NM_013247.4(HTRA2): c.695T> A (p.Leu232Gln) single nucleotide variant Uncertain significance rs869025234 GRCh37 Chromosome 2, 74757932: 74757932
34 HTRA2 NM_013247.4(HTRA2): c.695T> A (p.Leu232Gln) single nucleotide variant Uncertain significance rs869025234 GRCh38 Chromosome 2, 74530805: 74530805
35 LRAT NM_004744.4(LRAT): c.78T> A (p.Ser26Arg) single nucleotide variant Uncertain significance rs869025235 GRCh37 Chromosome 4, 155665556: 155665556
36 LRAT NM_004744.4(LRAT): c.78T> A (p.Ser26Arg) single nucleotide variant Uncertain significance rs869025235 GRCh38 Chromosome 4, 154744404: 154744404
37 CREB3 NM_006368.4(CREB3): c.823T> G (p.Tyr275Asp) single nucleotide variant Uncertain significance rs869025236 GRCh37 Chromosome 9, 35736430: 35736430
38 CREB3 NM_006368.4(CREB3): c.823T> G (p.Tyr275Asp) single nucleotide variant Uncertain significance rs869025236 GRCh38 Chromosome 9, 35736433: 35736433
39 ALOX5 NM_000698.4(ALOX5): c.490T> G (p.Leu164Val) single nucleotide variant Uncertain significance rs869025237 GRCh37 Chromosome 10, 45907697: 45907697
40 ALOX5 NM_000698.4(ALOX5): c.490T> G (p.Leu164Val) single nucleotide variant Uncertain significance rs869025237 GRCh38 Chromosome 10, 45412249: 45412249
41 KNDC1 NM_152643.7(KNDC1): c.2914G> T (p.Glu972Ter) single nucleotide variant Uncertain significance rs869025238 GRCh37 Chromosome 10, 135013889: 135013889
42 KNDC1 NM_152643.7(KNDC1): c.2914G> T (p.Glu972Ter) single nucleotide variant Uncertain significance rs869025238 GRCh38 Chromosome 10, 133200385: 133200385
43 PML NM_033238.2(PML): c.2264G> C (p.Arg755Pro) single nucleotide variant Uncertain significance rs780746013 GRCh37 Chromosome 15, 74336964: 74336964
44 PML NM_033238.2(PML): c.2264G> C (p.Arg755Pro) single nucleotide variant Uncertain significance rs780746013 GRCh38 Chromosome 15, 74044623: 74044623
45 ARHGAP35 NM_004491.4(ARHGAP35): c.1959_1960delGCinsAA (p.Pro654Thr) indel Uncertain significance rs869312173 GRCh38 Chromosome 19, 46920634: 46920635
46 ARHGAP35 NM_004491.4(ARHGAP35): c.1959_1960delGCinsAA (p.Pro654Thr) indel Uncertain significance rs869312173 GRCh37 Chromosome 19, 47423891: 47423892
47 RRP1 NM_003683.5(RRP1): c.340C> T (p.Arg114Cys) single nucleotide variant Uncertain significance rs763767114 GRCh37 Chromosome 21, 45213265: 45213265
48 RRP1 NM_003683.5(RRP1): c.340C> T (p.Arg114Cys) single nucleotide variant Uncertain significance rs763767114 GRCh38 Chromosome 21, 43793384: 43793384
49 FUBP1 NM_003902.4(FUBP1): c.1611G> A (p.Trp537Ter) single nucleotide variant Uncertain significance rs869025239 GRCh37 Chromosome 1, 78422351: 78422351
50 FUBP1 NM_003902.4(FUBP1): c.1611G> A (p.Trp537Ter) single nucleotide variant Uncertain significance rs869025239 GRCh38 Chromosome 1, 77956666: 77956666

Cosmic variations for Breast Ductal Carcinoma:

9 (show top 50) (show all 5317)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM51177 ZSWIM8 breast,NS,carcinoma,ductal carcinoma c.1563G>A p.K521K 10:73797261-73797261 0
2 COSM6937481 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.1406C>T p.S469L 23:15823199-15823199 0
3 COSM6925955 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.267G>C p.K89N 23:15803751-15803751 0
4 COSM6963999 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.1312G>T p.G438C 23:15823105-15823105 0
5 COSM6974238 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.1084G>A p.E362K 23:15822877-15822877 0
6 COSM6953912 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.989A>G p.H330R 23:15822782-15822782 0
7 COSM32591 ZNHIT2 breast,NS,carcinoma,ductal carcinoma c.175G>C p.A59P 11:65117479-65117479 0
8 COSM50437 ZNF830 breast,NS,carcinoma,ductal carcinoma c.136A>G p.N46D 17:34961702-34961702 0
9 COSM33456 ZNF668 breast,NS,carcinoma,ductal carcinoma c.196G>A p.A66T 16:31064264-31064264 0
10 COSM33234 ZNF668 breast,NS,carcinoma,ductal carcinoma c.992C>G p.T331R 16:31061936-31061936 0
11 COSM33435 ZNF668 breast,NS,carcinoma,ductal carcinoma c.856G>A p.G286S 16:31062072-31062072 0
12 COSM33584 ZNF646 breast,NS,carcinoma,ductal carcinoma c.4010A>T p.N1337I 16:31080334-31080334 0
13 COSM32207 ZNF644 breast,NS,carcinoma,ductal carcinoma c.157G>C p.E53Q 1:90941197-90941197 0
14 COSM32635 ZNF569 breast,NS,carcinoma,ductal carcinoma c.85C>G p.Q29E 19:37426309-37426309 0
15 COSM32954 ZNF532 breast,NS,carcinoma,ductal carcinoma c.2465C>T p.S822L 18:58934551-58934551 0
16 COSM33530 ZNF438 breast,NS,carcinoma,ductal carcinoma c.1143G>C p.K381N 10:30849262-30849262 0
17 COSM32744 ZNF318 breast,NS,carcinoma,ductal carcinoma c.3820G>C p.G1274R 6:43340178-43340178 0
18 COSM32924 ZNF281 breast,NS,carcinoma,ductal carcinoma c.1580T>C p.I527T 1:200408126-200408126 0
19 COSM33029 ZNF277 breast,NS,carcinoma,ductal carcinoma c.994A>T p.I332L 7:112339870-112339870 0
20 COSM32751 ZNF277 breast,NS,carcinoma,ductal carcinoma c.1335G>C p.L445F 7:112342711-112342711 0
21 COSM32755 ZNF25 breast,NS,carcinoma,ductal carcinoma c.61G>A p.E21K 10:37957501-37957501 0
22 COSM33510 ZNF22 breast,NS,carcinoma,ductal carcinoma c.386A>T p.H129L 10:45003754-45003754 0
23 COSM32252 ZNF10 breast,NS,carcinoma,ductal carcinoma c.257-3C>G p.? 12:133155500-133155500 0
24 COSM50670 ZMIZ2 breast,NS,carcinoma,ductal carcinoma c.491C>G p.A164G 7:44757500-44757500 0
25 COSM32244 ZMIZ1 breast,NS,carcinoma,ductal carcinoma c.1651C>G p.L551V 10:79298565-79298565 0
26 COSM50422 ZKSCAN2 breast,NS,carcinoma,ductal carcinoma c.1258G>A p.E420K 16:25246938-25246938 0
27 COSM32555 ZIC3 breast,NS,carcinoma,ductal carcinoma c.649C>G p.P217A 23:137567340-137567340 0
28 COSM33562 ZFYVE26 breast,NS,carcinoma,ductal carcinoma c.3491C>A p.A1164E 14:67785091-67785091 0
29 COSM50767 ZFHX4 breast,NS,carcinoma,ductal carcinoma c.5524G>A p.V1842M 8:76852445-76852445 0
30 COSM50766 ZFHX4 breast,NS,carcinoma,ductal carcinoma c.9752C>G p.A3251G 8:76863466-76863466 0
31 COSM3276869 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.4750C>T p.Q1584* 16:72797932-72797932 0
32 COSM6941446 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.9095A>C p.K3032T 16:72793587-72793587 0
33 COSM6845183 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.2143C>T p.R715* 16:72958003-72958003 0
34 COSM6933756 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.1444G>A p.E482K 16:72958702-72958702 0
35 COSM6946536 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.7667C>T p.A2556V 16:72795015-72795015 0
36 COSM6980784 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.8798C>G p.S2933C 16:72793884-72793884 0
37 COSM6942666 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.6871C>T p.Q2291* 16:72795811-72795811 0
38 COSM6940614 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.2714C>G p.A905G 16:72957432-72957432 0
39 COSM6933933 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.4468G>A p.E1490K 16:72798214-72798214 0
40 COSM6953107 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.611T>G p.F204C 16:72959535-72959535 0
41 COSM6954458 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.8043G>C p.K2681N 16:72794639-72794639 0
42 COSM4984432 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.3757C>T p.R1253C 16:72811684-72811684 0
43 COSM6934678 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.10111C>A p.L3371M 16:72788165-72788165 0
44 COSM6946621 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.7789C>A p.P2597T 16:72794893-72794893 0
45 COSM50608 ZFC3H1 breast,NS,carcinoma,ductal carcinoma c.2306C>A p.A769D 12:71634758-71634758 0
46 COSM32934 ZDHHC4 breast,NS,carcinoma,ductal carcinoma c.310C>T p.P104S 7:6582191-6582191 0
47 COSM33432 ZCCHC24 breast,NS,carcinoma,ductal carcinoma c.725G>C p.*242S 10:79386346-79386346 0
48 COSM32774 ZCCHC14 breast,NS,carcinoma,ductal carcinoma c.868C>G p.L290V 16:87417564-87417564 0
49 COSM50385 ZBTB39 breast,NS,carcinoma,ductal carcinoma c.295G>A p.V99I 12:57004623-57004623 0
50 COSM33515 ZBTB3 breast,NS,carcinoma,ductal carcinoma c.1271A>T p.H424L 11:62752544-62752544 0

Copy number variations for Breast Ductal Carcinoma from CNVD:

7 (show all 33)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 50888 11 119630000 120260000 Deletion Ductal carcinoma
2 57116 11 63100000 76700000 Amplification CCND1 Ductal carcinoma
3 58629 11 68930000 70160000 Gain Ductal carcinoma
4 58724 11 69230000 69780000 Gain Ductal carcinoma
5 59882 11 78860000 79330000 Deletion Ductal carcinoma
6 60225 11 84000000 88080000 Deletion Ductal carcinoma
7 60766 11 91240000 95940000 Deletion Ductal carcinoma
8 66468 12 2966849 2986303 Copy number FOXM1 Ductal carcinoma
9 98103 16 15360000 17700000 Gain Ductal carcinoma
10 99317 16 25030000 27880000 Gain Ductal carcinoma
11 101507 16 40000 40090000 Gain Ductal carcinoma
12 107663 17 16530000 18020000 Deletion Ductal carcinoma
13 109740 17 28800000 35400000 Amplification ERBB2 Ductal carcinoma
14 116392 17 6500000 10700000 Copy number TP53 Ductal carcinoma
15 117043 17 70920000 72340000 Gain Ductal carcinoma
16 126771 19 20810000 63790000 Gain Ductal carcinoma
17 127047 19 23780000 51950000 Gain Ductal carcinoma
18 128079 19 39420000 40350000 Gain Ductal carcinoma
19 131070 19 52760000 63790000 Gain Ductal carcinoma
20 153161 20 34860000 62370000 Gain Ductal carcinoma
21 153748 20 41100000 62435964 Amplification BMP7 Ductal carcinoma
22 166731 3 107740000 107880000 Deletion Ductal carcinoma
23 166830 3 108620000 110660000 Deletion Ductal carcinoma
24 167069 3 112930000 115910000 Deletion Ductal carcinoma
25 179845 3 99790000 104540000 Deletion Ductal carcinoma
26 196641 5 170120000 170210000 Gain Ductal carcinoma
27 196700 5 170690000 172750000 Gain Ductal carcinoma
28 215548 6 77380000 82650000 Deletion Ductal carcinoma
29 231989 8 110000 5150000 Deletion Ductal carcinoma
30 233354 8 124380000 129070000 Gain Ductal carcinoma
31 234986 8 140450000 141700000 Gain Ductal carcinoma
32 238072 8 29700000 38500000 Amplification FGFR1 Ductal carcinoma
33 239766 8 41480000 42480000 Gain Ductal carcinoma

Expression for Breast Ductal Carcinoma

Search GEO for disease gene expression data for Breast Ductal Carcinoma.

Pathways for Breast Ductal Carcinoma

Pathways related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 BRCA1 CCND1 CDH1 CTNNB1 EGFR ERBB2
2
Show member pathways
13.45 AR CCND1 EGFR ERBB2 MET PIP
3
Show member pathways
13.33 CDH1 CTNNB1 EGFR ERBB2 MET PIP
4
Show member pathways
13.31 CDH1 CTNNB1 EGFR ERBB2 ESR1 MET
5
Show member pathways
13.07 CTSD EGFR ESR1 PGR TFF1 VEGFC
6
Show member pathways
12.95 BRCA1 CCND1 CTNNB1 EGFR ERBB2 MET
7
Show member pathways
12.93 CCND1 CTNNB1 EGFR ERBB2 MET VEGFC
8
Show member pathways
12.87 AR CCND1 CDH1 CTNNB1 EGFR ERBB2
9 12.8 EGFR ERBB2 MET TP53 VEGFC
10
Show member pathways
12.76 CDH1 CTNNB1 EGFR MET VEGFC
11
Show member pathways
12.72 CDH1 CTNNB1 ERBB2 ESR1 MET TP53
12
Show member pathways
12.61 CCND1 EGFR ERBB2 MET TP53
13 12.58 AR CCND1 CDH1 CTNNB1 EGFR ERBB2
14
Show member pathways
12.52 BRCA1 CCND1 CDH1 EGFR ERBB2 ESR1
15 12.5 BRCA1 CCND1 EGFR ERBB2 MET TP53
16
Show member pathways
12.45 CTNNB1 EGFR ERBB2 MET TP53
17 12.44 CCND1 CDH1 CTNNB1 TP53
18
Show member pathways
12.4 CDH1 CTNNB1 EGFR ERBB2 MET VEGFC
19
Show member pathways
12.33 CCND1 EGFR ERBB2 ESR1 TFF1
20
Show member pathways
12.32 BRCA1 CCND1 CDH1 CTNNB1 EGFR ERBB2
21
Show member pathways
12.26 BRCA1 CCND1 ESR1 PGR
22
Show member pathways
12.22 CCND1 EGFR ERBB2 MET TP53
23 12.2 CCND1 CDH1 CTNNB1 EGFR TP53
24 12.17 EGFR ERBB2 MET VEGFC
25 12.15 CCND1 EGFR ERBB2 MET TP53
26
Show member pathways
12.12 BRCA1 CDH1 EGFR MET VEGFC
27
Show member pathways
12.12 AR CCND1 CTNNB1 EGFR ERBB2
28 12.1 CTSD EGFR MET TP53
29 12.1 CCND1 CTNNB1 EGFR ERBB2 ESR1 MET
30 12.08 CDH1 CTNNB1 MET NME1
31 12.02 CCND1 CTNNB1 ESR1 TP53
32 12.01 CCND1 CTNNB1 ERBB2 TP53
33 11.99 CCND1 CTNNB1 EGFR TP53
34
Show member pathways
11.97 EGFR ERBB2 ESR1 PGR
35
Show member pathways
11.89 CDH1 CTNNB1 EGFR MET
36
Show member pathways
11.88 EGFR ERBB2 ESR1
37
Show member pathways
11.87 AR ESR1 PGR
38 11.8 AR CCND1 CDH1 CTNNB1
39 11.79 AR BRCA1 CCND1 CTNNB1 EGFR
40 11.78 CDH1 CTNNB1 MET
41 11.77 BRCA1 ERBB2 TP53
42
Show member pathways
11.75 CCND1 EGFR ESR1
43 11.74 CTNNB1 EGFR ERBB2
44 11.72 BRCA1 ERBB2 TP53
45 11.72 CCND1 EGFR ESR1
46 11.71 EGFR ERBB2 MET TP53
47 11.68 BRCA1 CCND1 ERBB2
48 11.67 CCND1 CDH1 EGFR ERBB2 TP53
49 11.62 AR BRCA1 CCND1 CTNNB1
50 11.62 CDH1 CTNNB1 EGFR ERBB2 MET

GO Terms for Breast Ductal Carcinoma

Cellular components related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 9.26 CDH1 CTNNB1
2 protein-containing complex GO:0032991 9.17 AR BRCA1 CTNNB1 EGFR ESR1 RAD54L
3 basal plasma membrane GO:0009925 9.13 EGFR ERBB2 MET
4 nucleus GO:0005634 10.17 AR BRCA1 CCND1 CTNNB1 EGFR ERBB2
5 cytoplasm GO:0005737 10 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR

Biological processes related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 protein deubiquitination GO:0016579 9.99 AR BRCA1 ESR1 TP53
2 negative regulation of gene expression GO:0010629 9.98 CTNNB1 ESR1 NME1 PGR
3 positive regulation of gene expression GO:0010628 9.95 AR BRCA1 CTNNB1 ERBB2 PIP TP53
4 positive regulation of protein phosphorylation GO:0001934 9.93 CCND1 EGFR ERBB2 VEGFC
5 regulation of apoptotic process GO:0042981 9.93 BRCA1 CTNNB1 ESR1 NME1 TP53
6 cell proliferation GO:0008283 9.93 AR CTNNB1 EGFR ERBB2 MET TP53
7 transcription initiation from RNA polymerase II promoter GO:0006367 9.91 AR CCND1 ESR1 PGR
8 positive regulation of protein kinase B signaling GO:0051897 9.91 EGFR ERBB2 ESR1 MET
9 cell differentiation GO:0030154 9.91 CTNNB1 EGFR NME1 TFF1 TP53 VEGFC
10 positive regulation of transcription, DNA-templated GO:0045893 9.91 AR BRCA1 CDH1 CTNNB1 EGFR ESR1
11 liver development GO:0001889 9.85 CCND1 EGFR MET
12 phosphatidylinositol phosphorylation GO:0046854 9.85 EGFR ERBB2 ESR1 MET
13 cellular response to drug GO:0035690 9.83 EGFR NME1 TP53
14 response to estrogen GO:0043627 9.83 BRCA1 CCND1 ESR1
15 cellular response to growth factor stimulus GO:0071363 9.81 CTNNB1 EGFR ERBB2
16 response to estradiol GO:0032355 9.81 CCND1 CTNNB1 EGFR ESR1
17 steroid hormone mediated signaling pathway GO:0043401 9.79 AR ESR1 PGR
18 androgen receptor signaling pathway GO:0030521 9.77 AR BRCA1 CTNNB1
19 response to drug GO:0042493 9.73 CCND1 CDH1 CTNNB1 NME1 RAD54L VEGFC
20 positive regulation of cell cycle arrest GO:0071158 9.7 BRCA1 FAP TP53
21 cellular process GO:0009987 9.69 AR CTNNB1
22 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.69 BRCA1 TP53
23 morphogenesis of embryonic epithelium GO:0016331 9.68 CTNNB1 VEGFC
24 Leydig cell differentiation GO:0033327 9.67 AR CCND1
25 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.67 ESR1 TP53
26 DNA strand renaturation GO:0000733 9.66 RAD54L TP53
27 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.66 EGFR TP53
28 mitotic G1 DNA damage checkpoint GO:0031571 9.64 CCND1 TP53
29 positive regulation of execution phase of apoptosis GO:1900119 9.64 FAP TP53
30 negative regulation of ERBB signaling pathway GO:1901185 9.62 EGFR ERBB2
31 positive regulation of epithelial cell proliferation GO:0050679 9.62 EGFR ERBB2 NME1 VEGFC
32 epithelial cell differentiation involved in prostate gland development GO:0060742 9.59 AR CTNNB1
33 morphogenesis of an epithelial fold GO:0060571 9.58 AR EGFR
34 positive regulation of epithelial cell proliferation involved in prostate gland development GO:0060769 9.58 AR CTNNB1
35 mammary gland alveolus development GO:0060749 9.58 AR CCND1 ESR1
36 response to UV-A GO:0070141 9.57 CCND1 EGFR
37 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.56 AR PGR
38 positive regulation of transcription by RNA polymerase III GO:0045945 9.36 AR
39 positive regulation of MAPK cascade GO:0043410 9.33 AR CTNNB1 ERBB2
40 entry of bacterium into host cell GO:0035635 9.13 CDH1 CTNNB1 MET
41 cellular response to indole-3-methanol GO:0071681 8.8 BRCA1 CDH1 CTNNB1
42 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 AR BRCA1 CTNNB1 EGFR ESR1 MET
43 positive regulation of cell proliferation GO:0008284 10.09 AR CCND1 CTNNB1 EGFR VEGFC
44 negative regulation of cell proliferation GO:0008285 10.04 AR CTNNB1 NME1 TFF1 TP53

Molecular functions related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.93 CCND1 CTNNB1 EGFR ESR1 TP53
2 chromatin binding GO:0003682 9.91 AR CTNNB1 EGFR ESR1 TP53
3 protein dimerization activity GO:0046983 9.83 AR ERBB2 FAP PIP
4 transcription factor binding GO:0008134 9.83 AR CCND1 CTNNB1 ESR1 TP53
5 identical protein binding GO:0042802 9.81 BRCA1 CDH1 EGFR ERBB2 ESR1 MET
6 beta-catenin binding GO:0008013 9.74 AR CDH1 ESR1
7 ATPase binding GO:0051117 9.73 AR ESR1 PGR
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.67 EGFR ERBB2 MET
9 RNA polymerase II transcription factor binding GO:0001085 9.65 AR CTNNB1 TP53
10 steroid hormone receptor activity GO:0003707 9.63 AR ESR1 PGR
11 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.62 EGFR ERBB2 ESR1 MET
12 nuclear receptor activity GO:0004879 9.58 AR ESR1 PGR
13 nitric-oxide synthase regulator activity GO:0030235 9.55 EGFR ESR1
14 steroid binding GO:0005496 9.54 AR ESR1 PGR
15 protein phosphatase binding GO:0019903 9.35 CTNNB1 EGFR ERBB2 MET TP53
16 enzyme binding GO:0019899 9.28 AR BRCA1 CCND1 CTNNB1 EGFR ESR1
17 protein binding GO:0005515 10.23 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD

Sources for Breast Ductal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....